JPMorgan and B. Riley Set Praxis Targets Above $700 as Dual FDA Decisions Approach

JPMorgan lifts Praxis target to $725; B. Riley starts at $713. Both see strong upside as two potential approvals approach in the next 10 weeks.

JPMorgan and B. Riley Set Praxis Targets Above $700 as Dual FDA Decisions Approach
Credit: Praxis Precision Medicines
Already have an account? Sign in.